Premium
Nuclear factor‐κB expression as a novel marker of radioresistance in early‐stage laryngeal cancer
Author(s) -
Yoshida Kenji,
Sasaki Ryohei,
Nishimura Hideki,
Okamoto Yoshiaki,
Suzuki Yoko,
Kawabe Tetsuya,
Saito Miki,
Otsuki Naoki,
Hayashi Yoshitake,
Soejima Toshinori,
Nibu Kenichi,
Sugimura Kazuro
Publication year - 2010
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.21239
Subject(s) - radioresistance , immunohistochemistry , stage (stratigraphy) , univariate analysis , medicine , cancer , epidermal growth factor receptor , pathology , oncology , head and neck cancer , biopsy , cancer research , multivariate analysis , biology , radiation therapy , paleontology
Background. The aim of this study was to evaluate the significance of nuclear factor‐kappa B (NF‐κB) expression as a marker of radioresistance in early‐stage laryngeal cancer.Methods. Thirty‐five patients with local recurrence and 70 case‐matched patients without local recurrence were entered in this study. NF‐κB expression was compared with Bcl‐2 and epidermal growth factor (EGF) receptor expression by immunohistochemistry, using pretreatment biopsy specimens. The prognostic value of NF‐κB was also evaluated. Twenty‐nine recurrent tumors were compared with pretreatment tumors.Results. NF‐κB expression in pretreatment tumors significantly correlated with local tumor control ( p = .01), but bcl‐2 and EGF receptor expression did not. Only NF‐κB expression showed prognostic significance for local tumor control in both univariate and multivariate analyses ( p = .008 and .04, respectively). NF‐κB expression was markedly enhanced in 23 of 29 (80%) recurrent tumors.Conclusion. NF‐κB expression may be a novel marker of radioresistance in early‐stage laryngeal cancer. © 2009 Wiley Periodicals, Inc. Head Neck, 2010